Novartis Ag

Aurigene Discovery Technologies Limited

Aurigene Oncology Limited

Dinesh Chikkanna

Mark G Bock

Clive McCarthy

Sunil Kumar Panigrahi

Muralidhara Ramachandra

Ramulu Poddutoori

Henrik Moebitz

Chetan Pandit

Srinivasa Raju Sammeta

Leena Khare Satyam

Vinayak Vasantrao Khairnar

Wohlfahrt Gerd

Ramulu Poddutorri

Myllymaki Mikko

The present invention relates to substituted alkynylene compounds represented by the compounds of formula (I), pharmaceutically acceptable salts and stereoisomers thereof. The present invention further provides the therapeutic uses of the compounds of formula (I) as anti-cancer agents.

Substituted alkynylene compounds as anticancer agents

The present invention relates to substituted imidazolidin-2-one derivatives of formula (I) or pharmaceutically acceptable salts thereof. The present invention further provides the methods of preparation of compound of formula (I) and utility as PRMT5 inhibitors. The compounds are useful as medicaments in the treatment of conditions and disorders mediated by PRMT5, such as cancer, metabolic disorders, inflammation, autoimmune disease and hemoglobinopathies.

Substituted imidazolidin-2-one derivatives as PRMT5 inhibitors

The present invention relates to the derivatives of compound of formula (I) and pharmaceutically acceptable salts thereof. The present invention further provides the methods of preparation of compound of formula (I) and use thereof as PRMT5 inhibitors. The compounds are useful as medicaments in the treatment of conditions where PRMT5 inhibition is desired, such as cancer, metabolic disorders, inflammation, autoimmune disease and hemoglobinopathies.

Imidazolidin-2-one compounds as PRMT5 modulators

The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof. The compounds have been demonstrated as inhibitors of MEK and therefore may be useful in the treatment of hyperproliferative diseases (e.g., cancer and inflammation). 

Heterocyclic sulfonamide derivatives

The present invention relates to compounds of Formula I where R, R, X, R, R, W, R, R, and Rare as defined herein as well as pharmaceutically acceptable salts thereof. The compounds have been shown to act as MEK inhibitors which may be useful in the treatment of hyperproliferative diseases, like cancer and inflammation.

Growing community of inventors

Bengaluru, India

Dinesh Chikkanna